These results suggests that changes in miRNA-5196 expression occurred during TNF-α therapy could support more informed clinical decisions on the most appropriate treatment regimens for individual RA and AS patients than changes in CRP levels. The gene discussed is CRP; the disease is rheumatoid arthritis.